TS-075174 — Problem IL-2 and its receptor IL-2R are known to play multiple roles in shaping the immune response, including both immune activation and tolerance. Treatments activating effector cells against tumors are undermined by an autoinhibitory loop caused by endogenous IL-2 secreted from activated Teffs. …

TS-075158 — Problem The global immune checkpoint inhibitor (ICI) market is ~$60B. However, only ~20% of patients derive long-term survival benefit. The current standard of care biomarker Tumor Mutation Burden (TMB) performs poorly and there is no universal biomarker with robust validated predictive ability. Opportunity A companion diagnostic for identifying patients who benefit with ICI would unlock a large market by improving patient outcome and enabling a pan-cancer treatment indication that helps newer market entrants to better compete with incumbents. Solution Genomic Score that Predicts Survival: We have developed a pan-cancer genomic scoring system encompassing ~170 genes that predicts long term survival with immune checkpoint inhibition (ICI) Derivation: Developed from next-generation sequencing genomic data from 54 Neuroendocrine neoplasms who received ICIs at OSU Validation: Performed by analyzing and scoring 20,563 genomic alterations in 1,662 ICI treated patients with 10 different cancers from a publicly available dataset. (Samstein et al., Nature Genetics 2019). Broad Applicability: NSCLC, Melanoma, Colorectal Cancer, Bladder cancer and Neuroendocrine Neoplasms. Competitive Advantage The genomic score performed better than the TMB score (current standard of care) AUC of 0.87-0.95 for genomic score vs AUC of 0.57 for TMB Predictive of survival in 5 types of cancer including NSCLC Applications Biotech/Pharma companies: Develop a companion diagnostic to facilitate ICI drug development and improve patient outcome that leads to a new pan-cancer treatment indication that competes strongly with established players such as Keytruda and Opdivo which lose patent exclusivity within 3 years Payors/Nationalized Health Systems: Accurately predicting survival benefit helps maximize benefit from expenditure on ICI

TS-074822 — Personal protective equipment (PPE) remains predominantly passive, relying on material strength to absorb or deflect impacts after they occur. This approach is insufficient in high-risk environments where fast-moving debris, tool fragments, or ballistic threats can cause severe injury before mitig…

TS-069524 — The Need Global water scarcity is a critical issue, with many regions lacking access to clean and reliable water sources. Traditional water harvesting methods are often energy-intensive and inefficient. There is a pressing need for innovative, sustainable, and energy-efficient technologies to extra…

TS-066052 — Novel T-cells expressing the IL-2a receptor to enhance cancer cell targeting.

TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.

TS-064830 — The Need: In today's healthcare landscape, the management of oncology patients has evolved to resemble that of chronic illness, necessitating a shift towards holistic care models like Relationship-Based Care (RBC). As patients with chronic diseases, including cancer, live longer, healthcare prof…

TS-064718 — A clinical decision support tool for minimizing failure to rescue events at hospitals.

TS-064248 — The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…

TS-064242 — The Need: In the fast-evolving landscape of healthcare, the need for evidence-based guidelines in the evaluation and management of Pulmonary Embolism (PE) is paramount. With patients presenting diverse clinical profiles, there is a critical commercial demand for a comprehensive and reliable solution…